

Greater Manchester Medicines Management Group

Minutes of the meeting held on
Thursday 11th August 2022, 1- 3pm

Virtual meeting

Present:

Name	Title	Organisation	Representing	Oct	Nov	Feb	Mar	May	Jul	Aug
Dr Helen Burgess (HB)	GP MO Prescribing lead	NHS Manchester CCGs	GPs	A	✓	✓	✓		✓	
Petra Brown (PeB)	Chief Pharmacist	Pennine care NHS FT	GM Mental Health Organisations	✓	✓	✓	✓	✓	A	✓
Kate Rigden (KR)	Chief Finance Officer	NHS Oldham CCG	CCG finance leads	✓	✓	✓	✓	✓	✓	A
Mina Patel (MP)	Trust Finance Officer	MFT	Provider Finance					✓	✓	✓
Jay Hamilton (TBC)		HiM	Health Innovation Manchester (HiM)			TV	A	✓	A	A
Dr Ann Harrison (AH)	GP MO Prescribing lead	Trafford CCG	GPs	✓	✓	✓	A	✓	✓	✓
Robert Hallworth (RH)	Specialist Cancer Pharmacist	NHSE	NHSE Specialised Commissioning	✓	✓	✓	✓	✓	✓	✓
Dr Pete Budden	GP Prescribing lead	Salford CCG	GMMMG Clinical Reference Subgroup						✓	✓
Peter Howarth (PH)	Head of Medicines Management	Tameside & Glossop CCG	CCG MO leads	✓	✓	✓	✓	✓	✓	✓

Aneet Kapoor	Chair of the GM LPN	LPN	Pharmacy profession	✓	✓	✓	✓	✓	✓	A
Vacant seat			GM Secondary Care Clinicians							
Peter Marks (PM)	LPC Board Member	GM LPC	Community Pharmacy	✓	✓	A	✓	✓	✓	✓
Chris Haigh (CH)	HOMM	Bolton CCG	CCG MO leads and GMMMGM Digital subgroup						✓	✓
Luvjit Kandula (LK)	Chair – Community Pharmacy Provider Board (CPPB)	GM LPC	Community Pharmacy		A	A	✓	✓	A	✓
Lara Shah	Deputy HOMM	MHCC	GMMMGM Population health and inequalities subgroup						✓	✓
Fiona Meadowcroft (FC)	Interim Deputy Director Strategy – Integrated Care	MHCC	CCG Commissioning lead	✓	✓	✓	JW	A	A	✓
Kenny Li	HOMM	MHCC	GMMMGM Medicines Value subgroup					✓	A	✓
Faisal Bokhari	Deputy HOMM	T&G CCG	GMMMGM Pharmacy workforce subgroup					✓	✓	✓
Karen O'Brien (KO'B)	Regional Pharmacist	NHSEI	NHSEI	✓	✓	✓	✓	✓	A	A
Rob Bellingham	Managing Director Greater Manchester Joint Commissioning Team	The GM Joint Commissioning Board (MO)	Joint Commissioning Board	✓	✓	✓	A	✓	A	A
Paul Buckley (PaB)	Chief Pharmacist	Stockport FT	GM Chief pharmacists	A	✓	A	A	✓	✓	✓

Steve Simpson (SS)	Chief Pharmacist	Bolton FT	GM Chief pharmacists	✓	✓	✓	✓	✓	A	✓
Charlotte Skitterall (CS)	Chief Pharmacist	Manchester FT	Chair	✓	✓	✓	✓	✓	✓	✓
Claire Vaughan (CV)	Head of MO	Salford CCG	Vice Chair of GMMMGS and GMMMGS Medicines Safety subgroup	✓	✓	✓	✓	✓	✓	A
Dr Sanjay Wahie (SW)	Clinical Director	NHS Wigan CCG	GPs	✓	✓	✓	✓	✓	A	✓
Dr Peter Elton	SCN representatives	Strategic Clinical Network	Strategic Clinical Network	A	✓	✓	✓	✓	✓	✓
Vacant seat			Provider Board representative							
Vacant seat			Council representative for GM Social Services							
Vacant seat			GM Medical Directors							
Vacant seat			Lay representative							
Vacant seat			GM Public Health							
Monica Mason (MM)	Head of Prescribing Support	RDTC	Professional secretary	✓	✓	✓	✓	✓	A	✓
Andrew Martin (AM)	MO Pharmacist	GM Joint Commissioning team	GMMMGS support	✓	✓	✓	✓	✓	A	✓
Andrew White (AW)	Head of MO	GM Joint Commissioning team	GMMMGS support	✓	✓	✓	✓	✓	✓	✓
Dan Newsome (DN)	Principal pharmacist	RDTC	GMMMGS support	✓	✓	✓	✓	✓	✓	✓

1. General Business

1.1 Apologies

As above. Amanda Fox deputised for Kate Rigden

1.2 Declarations of Interest

Nil declared.

2.0 Minutes and actions from the last meeting

Minutes from the July meeting were approved for publication

There were two outstanding actions that the group were to be updated on (work plan and subgroup terms of reference but AW was not present for this discussion. MM agreed to seek an update from AW. It was noted that the Charter had been shared with the ICB Medical Director.

Action: MM to seek an update on outstanding actions from AW

3.0 Subgroup decisions for ratification

GMMMGM considered for approval the recommendations from the Clinical Reference Subgroup. It was noted that there is a significant cost saving of £1.2 - 2.4M/year across GM due to the availability of generic sitagliptin, this is without the possible undertaking of a switch programme. The group asked that an equality impact assessment be undertaken with regard the anti-reflux milk formula decision, and that the ICB has process for this which GMMMGM should utilise.

Following extensive GM wide consultation and discussion at its recent meeting, CRG also submitted for approval a statement supporting the GM wide use of edoxaban as per NHSE IIF. GMMMGM approved this statement for publication following a minor re-wording. It was recognised that this position may change later in the year, but that at this time and for the foreseeable future this position was appropriate. Prescribers on the group explained that these patients would be under regular review, and that any change in medication would only happen after an informed discussion with the patient. The group asked that secondary care colleagues ensure that their organisations support this GM wide position, and it was agreed that this would be requested at the next Trust Chief Pharmacists meeting. Community pharmacy representation asked that adequate notice be given to any change in the GM position to aid pharmacies in the management of stock levels.

It was suggested and agreed that GMMMGM should run a balance of the financial impact of its decisions, RDTC will prepare this and provide it to the meeting at regular intervals.

MM explained that decisions from the July meeting had been submitted to members of the ICB executive team for approval, and that the decisions from this meeting would also be submitted in a similar manner. An increasing number of requests were being received by the RDTC from across the system, as to the delay in publication of these decisions, GMMMGM agreed that prompt approval of these decisions by the ICB was required, recognising that ICB governance processes were still being agreed.

Actions: MM to submit GMMMGM decisions to ICB executive team and seek a prompt decision in order that the GMMMGM formulary can be updated in a timely manner. A balance sheet of GMMMGM decisions will be developed by RDTC. All sectors to support the implementation of the GM wide position on edoxaban following its approval by ICB.

4.0 Medicines Governance in the GM ICB

CS provided the group with an update from a very recent meeting with the ICB Medical Director and ICB governance, finance and transformation leads. Currently GMMMGM decisions are submitted to ICB executive team members as directed at the July GMMMGM meeting, as previous delegated authority and approval route through CCG Directors of Commissioning and Finance has ceased to exist with the abolishment of CCGs. It is now also understood that the Planning and Delivery Committee that GMMMGM was expected to transfer its reporting into, won't continue but that GMMMGM as the ICB Medicines Committee will report to the Quality and Performance committee of the ICB. The group discussed the query raised at GMMMGM around the scheme of delegation and it was confirmed by ICB governance leads that "Place" can delegate its budget to GMMMGM if so agreed.

It was confirmed in this meeting that GMMMG will continue in its role as the ICB Medicines Committee, and that its function should be strengthened. Discussions are underway regarding the authority delegated to GMMMG; terms of reference have been revised and a further meeting is anticipated in the next 2-3 weeks with the same group.

5.0 GMMMG Subgroup Reporting

Update reports were received from the GMMMG subgroups as follows:

Medicines Safety subgroup provided an update on the sodium valproate safety improvement plan and priorities identified as part of the national overprescribing review. GMMMG was asked to note the MO locality leads plan and the development of a webpage to present medicines safety initiative.

Clinical Reference Subgroup recommendations were considered and approved by GMMMG as per item 3. The minutes from the July CRG meeting were also presented.

Medicines Value subgroup updated GMMMG on their agreed work streams which included wAMD pathway redesign, rebate schemes and locality value plans. Financial impacts are being prepared for each workstream and will be available in due course. There was no ask of GMMMG at this stage, although GMMMG asked for clear delivery dates against each workstream.

Digital workstream group reported on the progress made with business intelligence, the GM Care Record and digital enabling tools for pharmacy. The group asked that GMMMG escalate the approval of their terms of reference, these are yet to be received into GMMMG however. There was also a request for BI needs to be supported, but GMMMG asked that further detail be returned in a formal paper.

Workforce subgroup had submitted a report to GMMMG in July and had not met since.

The Health Inequalities subgroup had no report to submit as they had not met recently.

6.0 Associated committees reporting

There were no reports submitted.

The group discussed the funding allocation for additional pharmacist support through NHSE. It was agreed that hosting agreements needed to be agreed quickly in order that this funding could be received. This will be taken to the next Trust Chief Pharmacist meeting.

PB updated GMMMG on the exercise being undertaken by mental health teams around the shared care consultation that is currently live. GMMMG encouraged all sectors to input into this GM wide consultation, which aims to improve care for patients across GM equitably.

7.0 AOB

It was announced that PH is retiring and GMMMG expressed their thanks to Peter for his support and commitment to GMMMG over many years, wishing him a very well deserved retirement. Secretariat will look at the membership as a whole in the coming weeks.

Date of next virtual meeting: Thursday 8th September 2022, 1 – 3pm